FDA Approves Iloperidone for Bipolar Disorder

The FDA has approved iloperidone tablets for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone is an atypical antipsychotic that acts as a dopamine D2/serotonin 5-HT2A receptor antagonist. The approval was based on a phase 3 trial showing significant improvement in symptoms with iloperidone compared to placebo. The drug has a well-known safety profile and is effective in managing bipolar I disorder. Common side effects include tachycardia, dizziness, and weight gain. Dosage should be titrated to avoid orthostatic hypotension. The drug is contraindicated in patients with hypersensitivity reactions.

Source link

error: Content is protected !!